1.50
-0.66%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Equillium
From its filings with the US Securities and Exchange Commission
Equillium is based in La Jolla, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker EQ. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported revenue of $41.1m.
We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. Our primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development.
EQ504 is a preclinical-stage, novel AhR modulator that in multiple translational models has been shown to have a therapeutically beneficial impact inducing anti-inflammatory cells and cytokines while reducing proinflammatory cells and cytokines and improving intestinal tissue barrier function and repair. We initially intend to develop EQ504 for the treatment of ulcerative colitis, or UC, and other gastrointestinal, or GI, diseases with potential indication expansion opportunities for the treatment of inflammatory lung diseases.
EQ302 is a preclinical-stage, first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery. Inhibiting IL-15 and IL-21 is believed to be an effective treatment approach for certain GI indications, including celiac disease. We have conducted preclinical development of EQ302, including in vivo pharmacology studies and formulation development, to further characterize and optimize the product candidate. We are evaluating further advancement of EQ302, including product manufacturing and toxicology studies capable of supporting a potential investigational new drug, or IND, filing and a first-in-human clinical study.
Quoted from its 10-K, filed 25 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Oct 2018
- Employees
- 13
- Website
- equilliumbio.com ↗
- Head office
- 2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Daniel BradburyExecutive Chairman of the Board, since 2017$189,982
- Mr. Bruce SteelPresident, Chief Executive Officer, Director, since 2017$684,392
- Dr. Stephen ConnellyPresident, Chief Scientific Officer, since 2017$519,427
- Ms. Christine ZedelmayerChief Operating Officer$506,237
- Mr. Peter ColabuonoDirector$22,372
- Ms. Martha DemskiIndependent Director$89,294
- Mr. Charles McdermottIndependent Director$71,794
- Dr. Mark PruzanskiIndependent Director$74,294
- Dr. Barbara TroupinIndependent Director$67,365
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 51
- Social
- 66
- Governance
- 31
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Equillium Inc possesses several strengths that contribute to its success in the market. Firstly, the company has a strong and experienced management team with deep expertise in the biotechnology industry. This enables them to make informed decisions and navigate complex challenges effectively. Secondly, Equillium has developed innovative and promising drug candidates that show great potential for treating severe autoimmune and inflammatory diseases. These candidates have generated positive results in clinical trials, creating a strong foundation for future success. Lastly, Equillium has established strategic partnerships with leading pharmaceutical companies, which provides access to additional resources, expertise, and distribution channels.
Weaknesses
- Despite its strengths, Equillium Inc also faces certain weaknesses that need to be addressed. The company heavily relies on a limited number of drug candidates in its pipeline, making it vulnerable to setbacks in clinical trials or market shifts. Additionally, Equillium's revenue streams heavily depend on successful drug development and commercialization, which carries inherent risks. Any delays or failures in these areas can significantly impact the company's financial performance. Furthermore, Equillium operates in a highly competitive industry, where other biotech companies are also striving to develop breakthrough therapies, increasing the need for continuous innovation and differentiation.
Opportunities
- Equillium Inc has several opportunities that can be leveraged to drive future growth. Firstly, there is an increasing demand for effective treatments for autoimmune and inflammatory diseases, representing a significant market opportunity for Equillium's drug candidates. As the prevalence of these diseases continues to rise, the company has the potential to capture a larger market share. Secondly, Equillium can explore collaborations and licensing agreements to expand its drug pipeline or acquire complementary technologies that align with its strategic goals. Furthermore, the advancements in precision medicine and personalized therapies open up new avenues for Equillium to develop targeted treatments, increasing their competitiveness and market positioning.
Threats
- Equillium Inc must also mitigate various threats that could impact its performance. Firstly, regulatory challenges and compliance requirements in the healthcare sector pose a risk to Equillium's drug development and commercialization efforts. Changes in legislation or stricter regulations can disrupt operations or result in delays and increased costs. Secondly, the possibility of clinical trial failures or unforeseen side effects associated with drug candidates can negatively impact Equillium's reputation and financial stability. Additionally, intense competition from other biotech companies, including both established players and emerging startups, poses a threat to Equillium's market share and profitability. Economic downturns and market volatility can also affect funding and investor sentiment, impacting Equillium's ability to secure necessary financial resources.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.